Featured Publications
Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, Bui D, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Bajema K. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation. Annals Of Internal Medicine 2023, 176: 1486-1497. PMID: 37903369, PMCID: PMC10620954, DOI: 10.7326/m23-1394.Peer-Reviewed Original ResearchConceptsAcute COVID-19Veterans Health AdministrationUntreated comparatorsThromboembolic eventsCOVID-19Severe COVID-19Target trial emulationSARS-CoV-2Post COVID-19 conditionIndex dateVenous thromboembolismBaseline characteristicsCumulative incidencePulmonary embolismAcute infectionMedian ageOral antiviralsTrial emulationVHA careOutpatient treatmentInternational ClassificationHealth AdministrationU.S. veteransVeterans AffairsOrgan systems
2024
Self-Reported Everyday Functioning After COVID-19 Infection
Iwashyna T, Smith V, Seelye S, Bohnert A, Boyko E, Hynes D, Ioannou G, Maciejewski M, O’Hare A, Viglianti E, Berkowitz T, Pura J, Womer J, Kamphuis L, Monahan M, Bowling C, Admon A, Akgun K, Anderson S, Aslan M, Au D, Backus L, Bajema K, Baraff A, Batten L, Berkowitz T, Bernstein T, Berry Wyatt K, Bogdan J, Bosworth H, Boucher N, Burwick N, Cabrales A, Cano J, Chai W, Chen J, Cheung K, Crothers K, Curtis J, Davis M, Del Monico E, Dobalian A, Doll J, Dominitz J, Eastment M, Fan V, Ferguson J, Floyd B, Fox A, Goetz M, Govier D, Green P, Hastings S, Hauschildt K, Hawkins E, Hebert P, Helfand M, Hickok A, Horowitz D, Hough C, Hu E, Ikuta K, Jones B, Jones M, Kamphuis L, Kaufman B, Knight S, Korpak A, Korpela P, Kumbier K, Langa K, Laundry R, Lavin S, Li Y, Linquist J, McCready H, Michel M, Miles A, Milne J, Monahan M, Morelli D, Mutalik P, Naylor J, Neiderhausen M, Newell S, Nugent S, Ong M, Osborne T, Peterson M, Peterson A, Prescott H, Rajeevan N, Reddy A, Rouse M, Rowneki M, Saha S, Saini S, Shah J, Shahoumian T, Shaukat A, Shepherd-Banigan M, Showalter W, Slatore C, Smith N, Smith B, Suri P, Sussman J, Takata Y, Teo A, Thomas E, Thomas L, Tuepker A, Veigulis Z, Vig E, Vranas K, Wang X, Wicks K, Winchell K, Wong E, Woods C, Wysham K, Yan L, Zulman D. Self-Reported Everyday Functioning After COVID-19 Infection. JAMA Network Open 2024, 7: e240869. PMID: 38427352, PMCID: PMC10907923, DOI: 10.1001/jamanetworkopen.2024.0869.Peer-Reviewed Original ResearchConceptsEveryday functioningActivities of daily livingSelf-reported everyday functioningCOVID-19 infectionImpact of COVID-19 infectionDaily livingVeterans AffairsCOVID-19 cohortDocumented COVID-19Instrumental activities of daily livingMatched pairs of participantsHealth-related quality of lifePairs of participantsCohort studyProportion of veteransControl cohortLife-space mobilityStudy of veteransCohort study of veteransUS Veterans AffairsHealth-related qualityDocumented COVID-19 infectionSelf-reportTarget trial emulationQuality of life
2023
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Bajema K, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, Yan L, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Ioannou G. Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Annals Of Internal Medicine 2023, 176: m22-3565. PMID: 37276589, PMCID: PMC10243488, DOI: 10.7326/m22-3565.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCOVID-19 symptom onsetCOVID-19-related outcomesSevere COVID-19Six-month outcomesCOVID-19 vaccinationCOVID-19 treatmentCOVID-19SARS-CoV-2Percent of participantsUntreated control participantsCause mortalitySymptom onsetMedian ageOral antiviralsVHA careOutpatient treatmentHospitalizationHealth AdministrationDay 31U.S. veteransVariant transmissionMost veteransVeterans AffairsOne month